PRN: Global Vasculitis Treatment Market to Grow at a CAGR of 4.2% 2017-2021: Loss of Patent Exclusivity of Branded Therapies is Hindering Growth

27/giu/2017 14:48:24 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Vasculitis Treatment Market to Grow at a CAGR of 4.2% 2017-2021: Loss of Patent Exclusivity of Branded Therapies is Hindering Growth

 
[27-June-2017]
 

DUBLIN, June 27, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Vasculitis Treatment Market 2017-2021" report to their offering.

Logo

The global vasculitis treatment market to grow at a CAGR of 4.20 % during the period 2017-2021.

The report, Global Vasculitis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is strategic alliances. Strategic alliances, formed in terms of licensing and collaboration, help in the co-development and commercialization of drugs in different regions. Such agreements ensure the in-flow of adequate funds from both the companies and help to reduce liability costs for individual companies in the case of failures and thereby, attract more venture investments.

According to the report, one of the major drivers for this market is promising pipeline. The market shows attractive growth opportunities for vendors globally because of the growing incidences of vasculitis and the rise in the aging population. The clinical drugs pipeline for vasculitis treatment is strong with several emerging therapies, featuring candidates in different stages of development, including first-in-class drugs with disease-modifying properties and better safety and efficacy profiles.

Further, the report states that o! ne of the major factors hindering the growth of this market is loss of patent exclusivity of branded therapies. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. This is expected to have a negative impact on the revenue of branded drugs used to treat vasculitis. In addition, the entry of generic versions of drugs will lead to a further loss of revenue for the drug manufacturers and hinder the growth of the market.

Key vendors

  • Bristol-Myers Squibb
  • CELGENE
  • F. Hoffmann-La Roche
  • GlaxoSmithKline

Other prominent vendors

  • Ablynx
  • AB SCIENCES
  • Acorda Therapeutics
  • Alder Biopharmaceuticals
  • Antares Pharma
  • Astellas Pharma
  • Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline landscape

PART 06: Market landscape

PART 07: Market segmentation by drug class

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/gwpq2z/global_vasculitis

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl